Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Severe hyperglycaemia following pazopanib treatment: The role of drug‐drug‐gene interactions in a patient with metastatic renal cell carcinoma—A case report (CROSBI ID 278878)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Kuruc Poje, Darija ; Božina, Nada ; Šimičević, Livija ; Žabić, Igor Severe hyperglycaemia following pazopanib treatment: The role of drug‐drug‐gene interactions in a patient with metastatic renal cell carcinoma—A case report // Journal of clinical pharmacy and therapeutics, 45 (2020), 4; 628-631. doi: 10.1111/jcpt.13160

Podaci o odgovornosti

Kuruc Poje, Darija ; Božina, Nada ; Šimičević, Livija ; Žabić, Igor

engleski

Severe hyperglycaemia following pazopanib treatment: The role of drug‐drug‐gene interactions in a patient with metastatic renal cell carcinoma—A case report

What is known and objective Pazopanib is a tyrosine kinase inhibitor with hyperglycaemia as a known adverse event, but case reports of severe hyperglycaemia are exceptional. We report a case of severe hyperglycaemia following pazopanib administration in a patient with metastatic renal cell carcinoma. Case summary Severe hyperglycaemia developed in a patient one month following initiation of pazopanib therapy. As drug‐drug‐gene interactions may lead to hyperglycaemia, pharmacogenetic assessment was requested. The obtained findings indicated intermediate function of both OATP1B1 and P‐glycoprotein transporters, which may cause prolonged pazopanib bioavailability and increased toxicity. Pazopanib was discontinued and, following patient recovery, was reintroduced at a lower dose. What is new and Conclusion The pharmacogenetic profiling of the patient on polypharmacy enabled better management of pazopanib therapy.

pazopanib ; case report ; hyperglycaemia ; polypharmacy ; drug-drug-gene interactions ; pharmacogenetics

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

45 (4)

2020.

628-631

objavljeno

0269-4727

1365-2710

10.1111/jcpt.13160

Povezanost rada

Kliničke medicinske znanosti

Poveznice
Indeksiranost